Revalesio Corp — SEC Form D Filing

Revalesio Corp filed an SEC Form D on December 16, 2025, reporting $38.88M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
December 16, 2025
Amount reported
$38.88M
Round stage
Series B+
Industry
Pharmaceuticals
Website
https://revalesio.com

Problem

Patients suffering from acute ischemic stroke and other neurological conditions currently have few therapeutic treatment options, leading to significant disability and reduced quality of life.

Solution

Revalesio develops a new class of drugs, exemplified by its lead candidate RNS60, which utilizes proprietary physics-based technology to address fundamental disease mechanisms and improve recovery in stroke and slow disease progression in chronic neurological conditions.

Why now

Revalesio is being started at this moment due to a regulatory shift, specifically the FDA's recent Fast Track Designation for RNS60, which accelerates the development and review of treatments for serious conditions with unmet medical needs like acute ischemic stroke.

Source: SEC EDGAR Form D filing